Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

Blood
J M AllanC P Wild

Abstract

The xeroderma pigmentosum group D (XPD) gene encodes a DNA helicase that functions in nucleotide excision repair of chemotherapy-induced DNA damage, the efficiency of which is predicted to be affected by a lysine to glutamine variant at codon 751. We hypothesized that this constitutive genetic variant may modify clinical response to chemotherapy, and we have examined its association with outcome following chemotherapy for acute myeloid leukemia (AML) in 341 elderly patients entered into the United Kingdom Medical Research Council AML 11 trial, and with the risk of developing chemotherapy-related AML. Among subjects treated for AML, disease-free survival at one year was 44% for lysine homozygotes, compared with 36% for heterozygotes and 16% for glutamine homozygotes (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.01-1.70; P = .04). Similarly, overall survival at one year was 38% for lysine homozygotes, 35% for heterozygotes, and 23% for glutamine homozygotes (HR, 1.18; 95% CI, 0.99-1.41; P = .07). Furthermore, homozygosity for the XPD codon 751 glutamine variant was associated with a significantly increased risk of developing AML after chemotherapy (odds ratio, 2.22 for Gln/Gln vs Lys/Lys; 95% CI, 1.04-4.74). These dat...Continue Reading

Citations

Jan 8, 2009·Breast Cancer Research and Treatment·Mary A BewickRobert M Lafrenie
Nov 19, 2005·Nature Reviews. Cancer·James M Allan, Lois B Travis
Mar 27, 2013·Nature Reviews. Clinical Oncology·Lois B TravisAndrea K Ng
Jan 5, 2006·Journal of the National Cancer Institute·Lois B TravisMark H Greene
Apr 15, 2011·Annals of Surgery·Jang-Ming LeeYung-Chie Lee
Oct 8, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Smita Bhatia
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Helen K ChewKathy S Albain
Sep 7, 2005·Pharmacogenomics·James M Allan, Charles S Rabkin
Aug 5, 2006·Pharmacogenomics·Eric KnocheTimothy A Graubert
Feb 5, 2008·Pharmacogenomics·Marc Ansari, Maja Krajinovic
Jan 21, 2014·Leukemia Research·Robert Peter GaleF Owen Hoffman
Jun 24, 2014·BioMed Research International·Claudia BănescuMinodora Dobreanu
Aug 27, 2014·Medical Oncology·Mehmet Burak AktugluBedia Cakmakoglu
Jan 31, 2008·Leukemia & Lymphoma·Vicent Guillem, Mar Tormo
Sep 14, 2007·Scandinavian Journal of Clinical and Laboratory Investigation·K M ThomsS Emmert
Dec 18, 2013·Seminars in Oncology·Smita Bhatia
Jan 19, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Claudia BănescuErzsebeth Lazar
Feb 2, 2010·Hematology/oncology Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Sep 9, 2009·Cancer Epidemiology·Lisa WorrillowTracy J Lightfoot
Nov 26, 2008·Leukemia Research·Emiliano FabianiMaria Teresa Voso
Apr 9, 2008·Hematology/oncology Clinics of North America·James M Allan
Feb 5, 2008·Pediatric Clinics of North America·Jeffrey E RubnitzFranklin O Smith
Nov 30, 2006·International Journal of Cancer. Journal International Du Cancer·Annette VangstedUlla Vogel
Jun 2, 2007·British Journal of Haematology·Claire Seedhouse, Nigel Russell
May 16, 2013·British Journal of Haematology·Maria C SusiniUNKNOWN Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators
Mar 17, 2010·International Journal of Cancer. Journal International Du Cancer·Jing-Yi ShiSai-Juan Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.